Business Context and Reporting Period
Bioaffinity Technologies, Inc. (BIAF) filed a Form 8-K Current Report on April 1, 2026. The company, incorporated in Delaware and listed on the Nasdaq Capital Market, operates as an emerging growth company. The report focuses on a specific operational milestone regarding its CyPath® Lung diagnostic product for the first quarter of 2026.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The only quantitative data disclosed relates to unit sales growth for the CyPath® Lung diagnostic.
- Unit Sales Growth (Q1 2026 vs. Q1 2025): 146% increase based on preliminary unaudited data.
- Performance vs. Projections: Exceeded internal projections for the first quarter of 2026.
Material Changes
The primary material change reported is the significant acceleration in unit sales for the CyPath® Lung diagnostic test. This 146% year-over-year growth reflects increased physician adoption and expanding clinical use of the company's noninvasive lung cancer diagnostic test.
Guidance, Outlook, and Risks
Management commentary indicates positive momentum driven by accelerating adoption. The filing references a press release (Exhibit 99.1) for further details but does not contain explicit forward-looking financial guidance, updated risk factors, or discussions of contingencies within the text of this 8-K. The data provided is preliminary and unaudited.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for detailed context on the sales figures.
- Verify the definition of "unit sales" to understand if this metric correlates directly with revenue recognition.
- Monitor upcoming quarterly earnings reports for audited financial results and confirmation of the growth trend.
- Assess the sustainability of the 146% growth rate in subsequent quarters.